Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 6/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7967359 | 0.91 | AVPR2 (0.35) | IRAK4 | |
| SCHEMBL7967095 | 0.90 | BRD4 (0.37) | IRAK4MEN1KMT2ATP53GAA | |
| SCHEMBL7969774 | 0.84 | MAP3K7 (0.38) | — | |
| SCHEMBL7482373 | 0.81 | BRD4 (0.34) | IRAK4ADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL7474173 | 0.80 | ADRA1D (0.32) | IRAK4ADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL7337787 | 0.78 | ALDH1A1 (0.41) | ADRA1DADRA1AADRA1BMEN1KMT2A | |
| SCHEMBL7335216 | 0.78 | MEN1 (0.46) | IRAK4ADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL7483103 | 0.78 | BRD4 (0.36) | IRAK4MEN1KMT2A | |
| SCHEMBL7970647 | 0.77 | MAP3K7 (0.38) | IRAK4GAA | |
| SCHEMBL7607734 | 0.77 | BRD4 (0.35) | IRAK4MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6316482-B1 | FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |